<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02389920</url>
  </required_header>
  <id_info>
    <org_study_id>2014-01-112</org_study_id>
    <nct_id>NCT02389920</nct_id>
  </id_info>
  <brief_title>Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <brief_summary>
    <textblock>
      Describe the purpose of the study: This study aims to evaluate the improvement of&#xD;
      Dasatinib-related adverse events and to evaluate the treatment effect and safety by measuring&#xD;
      the genetic response of nilotinib with nilotinib 400mg BID for 12 months in Philadelphia&#xD;
      chromosome-positive chronic myeloid leukemia patients intolerant to Dasatinib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of improvement of Dasatinib-related adverse events</measure>
    <time_frame>at 3 months of nilotinib treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Leukemia, Chronic Myeloid</condition>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nilotinib 400mg BID for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <arm_group_label>Nilotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women ≥ 19 years old&#xD;
&#xD;
          2. Performance status (ECOG) of 0, 1, or 2&#xD;
&#xD;
          3. Chronic phase or accelerated phase chronic myeloid leukemia being treated for more&#xD;
             than two weeks, switch to nilotinib.&#xD;
&#xD;
          4. Appropriate target organ function defined as;&#xD;
&#xD;
             - Bilirubin &lt; 1.5 X ULN- Liver function test, AST (SGOT) and ALT (SGPT) &lt; 2.5 X ULN-&#xD;
             Creatinine &lt; 1.5 X ULN- Serum amylase and lipase ≤ 1.5 X ULN- Alkaline phosphatase ≤&#xD;
             2.5 X ULN (only if not related to tumor)&#xD;
&#xD;
          5. Women of childbearing potential must have a negative pregnancy test (urine or serum)&#xD;
             within 7 days prior to the start of study drug administration.&#xD;
&#xD;
          6. Should have laboratory results as follows.&#xD;
&#xD;
             - Potassium ≥ LLN- Magnesium ≥ LLN- Phosphorus ≥ LLN&#xD;
&#xD;
          7. Voluntary, signed and dated informed consent prior to any study procedures being&#xD;
             performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with the T315I mutation&#xD;
&#xD;
          2. Mutation known to be associated with low sensitivity to nilotinib(e.g., Y253H, E255K,&#xD;
             E255V, F359V),&#xD;
&#xD;
          3. Cardiac function abnormalities as follows are found.&#xD;
&#xD;
               -  FEVI &lt; 45% or less than lower limit of normal of each center on ECG&#xD;
&#xD;
               -  QT interval cannot be measured on ECG&#xD;
&#xD;
               -  Complete right bundle branch block&#xD;
&#xD;
               -  Using a ventricular pacemaker&#xD;
&#xD;
               -  Congenital long QT syndrome or family history of long QT syndrome&#xD;
&#xD;
               -  Past or present clinically significant ventricular or atrial tachycardia&#xD;
&#xD;
               -  Clinically significant bradycardia at rest (&lt; 50 beats/min)&#xD;
&#xD;
               -  Regardless of toxicity after Dasatinib intake, QTc &gt; 480 msec (using the QTcF&#xD;
                  formula) at baseline ECG. If QTcF &gt; 480 msec and electrolytes are not within the&#xD;
                  normal range, it is necessary to correct electrolytes and re-assess the patient's&#xD;
                  QTc. According to the result of QTc, the investigator makes a decision on the&#xD;
                  patient's enrollment.&#xD;
&#xD;
               -  Myocardial infarction within 12 months prior to the start of the study&#xD;
&#xD;
               -  Other clinically significant heart disease (e.g., unstable angina, congestive&#xD;
                  heart failure or uncontrolled hypertension)&#xD;
&#xD;
          4. Cytopathologically confirmed central nervous system lumbar puncture (spinal tapping is&#xD;
             not needed if it is not suspected of association with central nervous system)&#xD;
&#xD;
          5. Severe or uncontrolled disease (e.g., uncontrolled diabetes mellitus, active or&#xD;
             uncontrolled infection)&#xD;
&#xD;
          6. History of significant congenital or acquired, bleeding disorder unrelated to cancer&#xD;
&#xD;
          7. 25% or more of bone marrow has been treated with prior radiotherapy&#xD;
&#xD;
          8. Not recovered from prior surgery or having a major surgery within 4 weeks from Day -1&#xD;
             of the study&#xD;
&#xD;
          9. Treated with other investigational product within 30 days&#xD;
&#xD;
         10. History of noncompliance with medical treatment or unable to voluntarily provide the&#xD;
             written signed and dated informed consent&#xD;
&#xD;
         11. Other primary cancer which is currently clinically significant and requires active&#xD;
             treatment&#xD;
&#xD;
         12. Currently treated with a strong CYP3A4 inhibitor (e.g., erythromycin, ketoconazole,&#xD;
             itraconazol, voriconazol, clarithromycin, telithromycin, ritonavir, mibefradil), and&#xD;
             the treatment cannot be stopped or switched to other drug before the start of study&#xD;
             drug administration (For a complete list, refer to this link:&#xD;
             http://medicine.iupui.edu/flockhart/table.htm.)&#xD;
&#xD;
         13. Gastrointestinal dysfunction or gastrointestinal disease that may significantly change&#xD;
             the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting,&#xD;
             diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass)&#xD;
&#xD;
         14. History of acute pancreatitis within the past 1 year or history of chronic&#xD;
             pancreatitis&#xD;
&#xD;
         15. Acute or chronic uncontrolled liver, pancreas or severe renal disease unrelated to the&#xD;
             disease&#xD;
&#xD;
         16. Currently treated with a drug which may prolong QT interval, and the treatment cannot&#xD;
             be stopped or switched to other drug before the start of study drug administration&#xD;
             (For a complete list of products which prolong QT interval, refer to&#xD;
             http://www.torsades.org/medical-pros/drug-lists/printable-drug-list.cfm)&#xD;
&#xD;
         17. Pregnant women, breast-feeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>March 11, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>March 16, 2015</last_update_submitted>
  <last_update_submitted_qc>March 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Chul Won Jung</investigator_full_name>
    <investigator_title>Samsung Medical Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

